Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
RCEL vs MYO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
RCEL Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)
RCEL Overall Winner
6-Pillar Tally: RCEL 3 – 2 MYO (1 Tie)
Matrix Metrics: RCEL 7 – 3 MYO
As of Nov 20, 2026, Avita Medical, Inc. (RCEL) is the stronger overall head-to-head candidate over Myomo Inc. (MYO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). RCEL carries a Unified Composite Score of 45.6/100 (HOLD) at $15.62 (10.3x Forward P/E, -33.9% operating margin), whereas MYO carries 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin).
- Technical & Structure Timing Caution: RCEL trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.5); meanwhile MYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About RCEL vs MYO
RCEL
Head-to-Head Winner
Avita Medical, Inc. Common Stock
$15.62
-2.31% 1D
Market Cap
$506.7M
TTM Revenue
$85M
Forward P/E
10.3x
Beta / 30D Vol
1.54β · 65% Vol
Unified Composite Score
45.6
HOLD
Tech 32.0
Fund 44.0
Flow 69.0
Mom 31.1
Weinstein Technical Phase
Markup · Hold / add on dips
MYO
Myomo Inc.
$0.81
-3.45% 1D
Market Cap
$33.7M
TTM Revenue
$46M
Forward P/E
N/M
Beta / 30D Vol
2.22β · 107% Vol
Unified Composite Score
40.1
SELL
Tech 25.0
Fund 43.0
Flow 58.0
Mom 59.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (RCEL 3 – 2 MYO)
1. Valuation Multiples
RCEL
Forward P/E
10.3x
N/M
Trailing P/E
10.3x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
6.4x
0.9x
2. Growth & Scale
RCEL
Revenue Growth (YoY)
+53.1%
+22.2%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$85M
$46M
Market Cap
$506.7M
$33.7M
3. Profitability & Quality
MYO
Gross Margin
82.4%
70.1%
Operating Margin
-33.9%
-21.8%
Net Profit Margin
-42.6%
-33.1%
Return on Equity (ROE)
-1746.3%
-173.5%
4. Balance Sheet & Cash Flow
MYO
Cash Generation (TTM)
-$20M
-$9.1M
Cash Flow Margin
-23.6%
-20.0%
Net Cash / Leverage
$37M Net Debt
$8.9M Net Debt (3.44x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
RCEL
Options Structure Phase
CONSOLIDATION
UNCLASSIFIED
Current IV / %ile
84.7% (6th %ile)
266.0% (81st %ile)
Put/Call OI Skew
0.18x (Call-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: RCEL (7) vs MYO (3)| Institutional Metric | RCEL | MYO | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $506.7M | $33.7M | RCEL | |
| Trailing P/E Ratio | 10.3x | N/M | RCEL | |
| Forward P/E Ratio | 10.3x | N/M | RCEL | |
| Revenue Growth (YoY) | +53.1% | +22.2% | RCEL | |
| Operating Margin (TTM) | -33.9% | -21.8% | MYO | |
| Net Profit Margin | -42.6% | -33.1% | MYO | |
| Return on Equity (ROE) | -1746.3% | -173.5% | MYO | |
| 52-Week Range Position | 82% ($3–$18) | 16% ($1–$2) | RCEL | |
| Beta / 30D Volatility | 1.54β · 65% Vol | 2.22β · 107% Vol | RCEL | |
| Unified Institutional Score | 45.6 / 100 (HOLD) | 40.1 / 100 (SELL) | RCEL | |
| Trailing 12M Revenue (USD) | $85M | $46M | Scale | |
| Gross Profit Margin (TTM) | 82.4% | 70.1% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 6.4x EV/Rev | N/M PEG · 0.9x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$20M ($37M Net Debt) | -$9.1M ($8.9M Net Debt (3.44x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
RCEL +34.82 pp
3M Horizon
RCEL +99.27 pp
6M Horizon
RCEL +263.07 pp
1Y Horizon
RCEL +283.14 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | RCEL Revenue | MYO Revenue | RCEL Op. Margin | MYO Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | $0M | -1489.9% | -430.8% | MYO |
| FY2019 | $10M | $0M | -466.4% | -281.3% | MYO |
| FY2020 | $10M | $10M | -299.2% | -138.5% | MYO |
| FY2021 | $30M | $10M | -90.8% | -74.1% | MYO |
| FY2022 | $30M | $20M | -79.9% | -68.6% | MYO |
| FY2023 | $50M | $20M | -85.1% | -42.8% | MYO |
| FY2024 | $60M | $30M | -88.1% | -19.1% | MYO |
| FY2025 | $70M | $40M | -59.4% | -35.2% | MYO |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
RCEL
CONSOLIDATION
Current IV
84.7%
IV Percentile
6th %ile
Put/Call OI Skew
0.18x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact RCEL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
MYO
UNCLASSIFIED
Current IV
266.0%
IV Percentile
81st %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact MYO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
RCEL Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
MYO Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ RCEL vs MYO Key Questions & Quantitative Answers
As of Nov 20, 2026, Avita Medical, Inc. (RCEL) is the stronger overall head-to-head candidate over Myomo Inc. (MYO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). RCEL carries a Unified Composite Score of 45.6/100 (HOLD) at $15.62 (10.3x Forward P/E, -33.9% operating margin), whereas MYO carries 40.1/100 (SELL) at $0.81 (N/M Forward P/E, -21.8% operating margin). Technical & Structure Timing Caution: RCEL trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.5); meanwhile MYO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
RCEL leads the Growth & Scale pillar: RCEL posts +53.1% YoY revenue growth and +0.0% YoY earnings growth on $85M TTM revenue (82.4% gross margin, -33.9% operating margin), compared with MYO at +22.2% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (70.1% gross margin, -21.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RCEL cumulative revenue shifted +600.0% while MYO shifted +300.0%. In operating R&D and SG&A reinvestment, RCEL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MYO.
RCEL screens cheaper on headline valuation multiples. RCEL trades at 10.3x Forward P/E, 10.3x Trailing P/E, N/M PEG, and 6.4x EV/Revenue (-23.6% FCF margin), whereas MYO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-20.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RCEL (-1746.3% ROE) versus MYO (-173.5% ROE) capital efficiency.
In options market volatility and institutional positioning, RCEL carries 84.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.54β · 65% Vol realized risk). By comparison, MYO carries 266.0% implied volatility (81st %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.22β · 107% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
MYO vs RCEL · Reverse Pair
RCEL vs SIBN
· Sector Peer
RCEL vs ORIC
· Sector Peer
RCEL vs PROF
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking